Natixis Advisors, L.P. Acadia Pharmaceuticals Inc Transaction History
Natixis Advisors, L.P.
- $63 Billion
- Q2 2025
A detailed history of Natixis Advisors, L.P. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 72,178 shares of ACAD stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
72,178
Previous 62,895
14.76%
Holding current value
$1.55 Million
Previous $1.05 Million
49.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ACAD
# of Institutions
345Shares Held
163MCall Options Held
811KPut Options Held
334K-
Baker Bros. Advisors LP New York, NY42.9MShares$924 Million9.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.3MShares$329 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$260 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY9MShares$194 Million2.98% of portfolio
-
State Street Corp Boston, MA6.18MShares$133 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.49B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...